Acquisitions, Mergers & PartnershipsBioinksBioprinting

Rousselot partners with Terasaki Institute for Biomedical Innovation

Collaborations focuses on the development of gelatin-based therapies and their translation to the clinic

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

Rousselot, Darling Ingredients’ health brand and the world’s leader of collagen-based solutions, has partnered with the Terasaki Institute for Biomedical Innovation (TIBI), a California-based research institute focused on regenerative medicine. Through this strategic partnership, Rousselot and TIBI will collaborate on the development of gelatin-based therapies and their translation to the clinic. Rousselot will supply TIBI with X-Pure modified gelatins such as X-Pure GelMA, while exchanging insights on the behavior of gelatin in the institute’s research and clinical trials.

With more than 130 years of gelatin and collagen expertise, Rousselot created X-Pure, a full range of biomedical gelatins and modified gelatins, characterized by their unmatched purity (<10EU/g endotoxin) and consistency, as well as full compliance with GMP. Part of this range, Rousselot’s X-Pure GelMA modified gelatins have already been tested and recognized for their premium quality by TIBI’s researchers.

Rousselot partners with Terasaki Institute for Biomedical Innovation on development of gelatin-based therapies and translation to clinic “We are excited to partner with Rousselot and to be able to use Rousselot’s modified gelatins for our research,” explains Ali Khademhosseini, CEO of Terasaki Institute for Biomedical Innovation. “Modified gelatins have proven to be powerful biomaterials in the regenerative medicine field, and we have been using them heavily over the past few years. I am certain that high-quality, purified GelMA will support both our in vitro and in vivo research and development. With X-Pure GelMA, we will be able to make further strides in the clinical translation of our research to accelerate the development of new therapies.”

“We are delighted to work together with TIBI and its team of world-renowned researchers,” said Jos Vervoort, Rousselot’s Executive Vice-President. “X-Pure modified gelatins are low-endotoxin, batch-to-batch consistent and GMP ready, making them suitable for research and clinical translation. Their purity and scalability will support the full cycle of research and clinical development and we are proud to play a role in helping the experts at TIBI translate their research into viable biomedical solutions that can help patients across the planet.”

The Partnership is effective from January 1st, 2022, and will have an initial duration of two years, fostering a close collaboration between TIBI’s experts on microneedles and 3D-bioprinting and Rousselot’s experts in collagen- and gelatin-based biomaterials.

Composites AM 2024

746 composites AM companies individually surveyed and studied. Core composites AM market generated over $785 million in 2023. Market expected to grow to $7.8 billion by 2033 at 25.8% CAGR. This new...

Davide Sher

Since 2002, Davide has built up extensive experience as a technology journalist, market analyst and consultant for the additive manufacturing industry. Born in Milan, Italy, he spent 12 years in the United States, where he completed his studies at SUNY USB. As a journalist covering the tech and videogame industry for over 10 years, he began covering the AM industry in 2013, first as an international journalist and subsequently as a market analyst, focusing on the additive manufacturing industry and relative vertical markets. In 2016 he co-founded London-based VoxelMatters. Today the company publishes the leading news and insights websites and, as well as VoxelMatters Directory, the largest global directory of companies in the additive manufacturing industry.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close Popup
Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

Technical Cookies
In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services


Join our 12,000+ Professional community and get weekly AM industry insights straight to your inbox. Our editor-curated newsletter equips executives, engineers, and end-users with crucial updates, helping you stay ahead.